CN111793113B - Synthesis, activity and application of dihydroxymethyl tetrahydrocarboline-3-formyl-The-HGK - Google Patents
Synthesis, activity and application of dihydroxymethyl tetrahydrocarboline-3-formyl-The-HGK Download PDFInfo
- Publication number
- CN111793113B CN111793113B CN201910273811.1A CN201910273811A CN111793113B CN 111793113 B CN111793113 B CN 111793113B CN 201910273811 A CN201910273811 A CN 201910273811A CN 111793113 B CN111793113 B CN 111793113B
- Authority
- CN
- China
- Prior art keywords
- carboline
- tetrahydro
- formyl
- gly
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 dihydroxymethyl Chemical group 0.000 title claims description 18
- 230000000694 effects Effects 0.000 title abstract description 17
- 230000015572 biosynthetic process Effects 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 206010027476 Metastases Diseases 0.000 claims abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 13
- 230000009401 metastasis Effects 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 13
- NQKRILCJYCASDV-QWRGUYRKSA-N His-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 NQKRILCJYCASDV-QWRGUYRKSA-N 0.000 claims description 11
- ULBGQMDUNSJLSE-UMJHXOGRSA-N (3S)-1,1-bis(hydroxymethyl)-2,3,4,4a-tetrahydropyrido[3,4-b]indole-3-carboxylic acid Chemical compound C(O)C1(N[C@@H](CC2C3=CC=CC=C3N=C12)C(=O)O)CO ULBGQMDUNSJLSE-UMJHXOGRSA-N 0.000 claims description 10
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- JYMMEXBKOPNBLO-IJHRGXPZSA-N CC(C)(C)[Si](C)(C)OC(C1=NC2=CC=CC=C2C1C1)(N(C)[C@@H]1C(O)=O)O[Si](C)(C)C(C)(C)C Chemical compound CC(C)(C)[Si](C)(C)OC(C1=NC2=CC=CC=C2C1C1)(N(C)[C@@H]1C(O)=O)O[Si](C)(C)C(C)(C)C JYMMEXBKOPNBLO-IJHRGXPZSA-N 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000009833 condensation Methods 0.000 claims description 6
- 230000005494 condensation Effects 0.000 claims description 6
- 239000007791 liquid phase Substances 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- DRKCFXGMGKTUEH-QWAKEFERSA-N COC(=O)[C@H]1N(C(C2=NC3=CC=CC=C3C2C1)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)C Chemical compound COC(=O)[C@H]1N(C(C2=NC3=CC=CC=C3C2C1)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)C DRKCFXGMGKTUEH-QWAKEFERSA-N 0.000 claims description 4
- ZRUBCNOEBUECNG-KFJBMODSSA-N methyl (3S)-1,1-bis(hydroxymethyl)-2,3,4,4a-tetrahydropyrido[3,4-b]indole-3-carboxylate Chemical compound COC(=O)[C@H]1NC(C2=NC3=CC=CC=C3C2C1)(CO)CO ZRUBCNOEBUECNG-KFJBMODSSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- 210000004027 cell Anatomy 0.000 description 33
- 239000000243 solution Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000006285 cell suspension Substances 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000008034 disappearance Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 4
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 4
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000010936 aqueous wash Methods 0.000 description 2
- WFDXYGGWXJNVOU-QHCPKHFHSA-N benzyl (2s)-2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound C([C@H](NC(=O)CNC(=O)OC(C)(C)C)C(=O)OCC=1C=CC=CC=1)CCCNC(=O)OCC1=CC=CC=C1 WFDXYGGWXJNVOU-QHCPKHFHSA-N 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PXJIFXYRDCCTSO-UHFFFAOYSA-N CC(C1=C(C2)C3=CC=CC=C3N1)NC2C(OO[Si](C)(C)C(C)(C)C)=O Chemical compound CC(C1=C(C2)C3=CC=CC=C3N1)NC2C(OO[Si](C)(C)C(C)(C)C)=O PXJIFXYRDCCTSO-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- KWJZVBPCHFDTKO-UHFFFAOYSA-N methyl 1,1-bis(hydroxymethyl)pyrido[3,4-b]indole-3-carboxylate Chemical compound COC(=O)C1=NC(C2=NC3=CC=CC=C3C2=C1)(CO)CO KWJZVBPCHFDTKO-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The invention discloses (3S) -1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys, a preparation method of The compound, and antitumor activity and antitumor metastasis activity of The compound. Therefore, the invention discloses the application of the compound in preparing the anti-tumor and anti-tumor metastasis medicaments.
Description
Technical Field
The invention relates to (3S) -1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys, a preparation method thereof, and antitumor activity and antitumor metastasis activity thereof. Therefore, the invention relates to the application of the compound in preparing anti-tumor drugs and anti-tumor metastasis drugs. The invention belongs to the field of biological medicine.
Background
Mortality and morbidity rates for malignant tumors have risen year by year, both in developed and developing countries. In China, malignant tumors have become the first fatal disease. It is well known that almost all malignant tumors can metastasize through the blood or lymphatic channels. Numerous clinical studies have shown that over 70% of the deaths from malignant tumors are metastatic. The invention relates to a medicament with dual functions of resisting tumor and tumor metastasis, which is one of the leading fields of biological medicine. Also, the group in which people were invented during the last decade has paid a hard creation for the invention of drugs with dual action against tumors and tumor metastases. Meanwhile, the inventor finds that (3S) -1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-carboxylic acid is a potential pharmacophore. Then, The inventors found that The (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys having The following structure, which is produced by modifying The carboxyl group of The (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-carboxylic acid with The-His-Gly-Lys, has dual effects of anti-tumor and anti-tumor metastasis. Based on this finding, the inventors have come up with the present invention.
Disclosure of Invention
The first aspect of The present invention provides (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys of The following structure.
The second aspect of The present invention provides a process for The preparation of (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys, which comprises 10 steps:
the first step is to prepare (3S) -1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-carboxylic acid;
the second step is to prepare (3S) -1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-carboxylic acid methyl ester;
the third step is to prepare (3S) -1, 1-di (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-carboxylic acid methyl ester;
the fourth step is to prepare (3S) -1, 1-di (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-carboxylic acid;
the fifth step is to prepare (3S) -1, 1-di (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-formyl-The-OMe by adopting Dicyclohexylcarbodiimide (DCC) as a condensing agent and 1-hydroxybenzotriazole (HOBt) as a catalyst through liquid phase condensation;
the sixth step is to prepare (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-formyl-The;
the seventh step is to prepare HCl, His-Gly-Lys (z) -OBzl by liquid phase condensation by using DCC as a condensing agent and HOBt as a catalyst;
the eighth step is to prepare (3S) -1, 1-di (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys (z) -OBzl by liquid phase condensation with DCC as a condensing agent and HOBt as a catalyst;
the ninth step is to prepare (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys;
the tenth step is The preparation of (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys;
the third aspect of The present invention is to evaluate (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys
Anti-tumor activity and anti-tumor metastasis activity.
Drawings
FIG. 1 is a synthetic route for (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys: i) h 2 SO 4 (ii), (1, 3-dihydroxyacetone); ii) thionyl chloride, CH 3 OH; iii) tert-butyldimethylchlorosilane (TBDMSCl), imidazole (imidazole); iv) CH 3 OH, NaOH; v) DCC, HOBt, N-methylmorpholine (NMM); vi) Pd/C, H 2 (ii) a vii) hydrogen chloride in ethyl acetate.
Detailed Description
To further illustrate the invention, a series of examples are given below. These examples are purely illustrative and are intended to be a detailed description of the invention only and should not be taken as limiting the invention.
EXAMPLE 1 preparation of (3S) -1, 1-dimethylol-tetrahydro-beta-carboline-3-carboxylic acid (1)
To 50mL of distilled water was added 3.06g (15mmol) of L-tryptophan, and the mixture was stirred well to suspend the tryptophan. And slowly dropwise adding concentrated sulfuric acid into the suspension under an ice bath condition until the L-tryptophan is completely dissolved. Then, 1.62g (18mmol) of 1, 3-dihydroxyacetone was added to the solution and reacted at room temperature for 84 hours. TLC showed the disappearance of L-tryptophan (ethyl acetate/water/glacial acetic acid, 4/1/1). Filtration and washing of the filter cake with ice water gave 2.90g (70%) of the title compound as a yellow powder.
EXAMPLE 2 preparation of (3S) -1, 1-dimethylol-tetrahydro-beta-carboline-3-carboxylic acid methyl ester (2)
4.7mL of thionyl chloride was slowly added dropwise to 50mL of methanol in ice bath, and after stirring for 30 minutes, 5.0g (18mmol) of (3S) -1, 1-dimethylol-tetrahydro- β -carboline-3-carboxylic acid (1) was added thereto. Stir until compound 1 is completely dissolved. Thereafter, the mixture was stirred at room temperature for 10 hours. TLC showed the disappearance of compound 1 (dichloromethane/methanol, 20: 1). The reaction mixture was concentrated under reduced pressure, and the residue was triturated with ethyl acetate. The supernatant was removed and the residue was triturated with ethyl acetate. The resulting brown-yellow solid was dissolved in 100mL of ethyl acetate. The solution was sequentially treated with saturated NaHCO 3 The aqueous solution and saturated NaCl were washed with water, and the ethyl acetate layer was dried over anhydrous sodium sulfate for 12 hours. Filtration and concentration of the filtrate under reduced pressure gave 4.73g (90%) of the title compound as a yellow solid. ESI-MS (M/e):291[ M + H] + 。
Example 3 preparation of (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-carboxylic acid methyl ester (3)
To 50mL of anhydrous N, N-Dimethylformamide (DMF) was added 4.35g (15mmol) of methyl 1, 1-dimethylol- β -carboline-3-carboxylate (2). Stirring until the compound 2 is completely dissolved. Thereafter, 3.66g (64.8mmol) of imidazole was added to the solution under ice-bath. Stirring until imidazole is completely dissolved. Thereafter, 6.79g (45mmol) of t-butyldimethylsilyl chloride (TBDMSCl) was added to the solution. The reaction mixture was stirred at room temperature for 6 hours. TLC showed the disappearance of compound 2 (petroleum ether/ethyl acetate, 20/1). The reaction mixture was concentrated under reduced pressure, and the residue was diluted with 100mL of saturated aqueous NaCl solution. The resulting solution was extracted with ethyl acetate (60 mL. times.3), and the ethyl acetate layer was then successively replaced with saturated NaHCO 3 The mixture was washed with an aqueous solution (30 mL. times.3) and a saturated aqueous NaCl solution (30 mL. times.3), and dried over anhydrous sodium sulfate for 12 hours. Filtering, and concentrating the filtrate under reduced pressure. The yellow residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate, 10/1) to give 4.82g (88%) of the title compound as a colorless solid. ESI-MS (M/e):519[ M + H] + 。
Example 4 preparation of (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-carboxylic acid (4)
To 40mL of a tetrahydrofuran/methanol (v/v, 1/1) mixed solution was added 5.18g (10mmol) of methyl (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro- β -carboline-3-carboxylate (3). Stirring until compound 3 is completely dissolved. An aqueous NaOH solution (4M) was added dropwise to the solution in an ice bath to adjust the pH of the reaction solution to 13. After stirring for 30min, TLC showed the disappearance of compound 3 (petroleum ether/ethyl acetate, 20/1). Adding saturated KHSO dropwise into the reaction mixture under ice bath 4 The pH of the aqueous solution was adjusted to 7. The reaction mixture was concentrated under reduced pressure. Under ice-bath, the residue was added dropwise with saturated KHSO 4 The pH of the aqueous solution was adjusted to 2. The resulting solution was extracted with ethyl acetate (30 mL. times.3), and the ethyl acetate layer was washed with a saturated aqueous NaCl solution and dried over anhydrous sodium sulfate for 12 hours. Filtration and concentration of the filtrate under reduced pressure gave 4.64g (90%) of the title compound as a colorless powder. ESI-MS (M/e) 505[ M + H ]] + 。
EXAMPLE 5 preparation of (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro- β -carboline-3-formyl-The-OMe (5)
To 50mL of DMF were added 5.04g (10mmol) of (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro- β -carboline-3-carboxylic acid (4), 2.47g (12mmol) of N, N' -Dicyclohexylcarbodiimide (DCC) and 1.62g (12mmol) of 1-hydroxybenzotriazole (HOBt). Stir for 30 minutes in an ice bath. Then, 2.48g (11mmol) of HCl. The-OMe was added to The reaction mixture. Subsequently, N-methylmorpholine (NMM) was added dropwise to the reaction mixture to adjust the pH of the reaction mixture to 9. Stir at rt for 6 h, TLC showed the disappearance of compound 4 (dichloromethane/methanol, 30/1). Dicyclohexylurea (DCU) was filtered off and the filtrate was concentrated under reduced pressure. The residue was dissolved in 60mL of ethyl acetate and the solution was filtered to remove DCU. The filtrate was sequentially treated with 5% NaHCO 3 Aqueous solution (30 mL. times.3), saturated aqueous NaCl solution (30 mL. times.3), 5% KHSO 4 Aqueous wash (30 mL. times.3), saturated aqueous NaCl wash (30 mL. times.3), 5% NaHCO 3 The mixture was washed with an aqueous solution (30 mL. times.3) and with a saturated aqueous NaCl solution (30 mL. times.3), and dried over anhydrous sodium sulfate for 12 hours. Filtration and concentration of the filtrate under reduced pressure gave a yellow powder which was purified by silica gel column chromatography (petroleum ether/ethyl acetate, 10/1) to give 5.4g (80%) of the titled compoundCompound, colorless powder. ESI-MS (M/e):675[ M + H] + 。
EXAMPLE 6 preparation of (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro- β -carboline-3-formyl-The (6)
Using The method of example 4, 2.64g (80%) of The title compound were obtained as colorless powder from 3.72g (5mmol) of (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro- β -carboline-3-formyl-The-OMe (5). ESI-MS (M/e):661[ M + H] + 。
EXAMPLE 7 preparation of Boc-Gly-Lys (z) -OBzl
Using the method of example 5, 2.12g (80%) of the title compound was obtained as a colorless solid from 0.96g (5.5mmol) of Boc-Gly and 1.85g (5mmol) of Hcl.Lys (z) -OBzl.
EXAMPLE 8 preparation of HCl.Gly-Lys (z) -OBzl
1.58g (3mmol) of Boc-Gly-Lys (z) -OBzl was dissolved in 20mL of hydrogen chloride in ethyl acetate (4M) under ice-bath conditions and reacted for 4 hours. TLC showed the disappearance of starting material (dichloromethane/methanol, 30/1). The reaction mixture was concentrated under reduced pressure, the residue was dissolved in anhydrous ethyl acetate, and the resulting solution was concentrated under reduced pressure. This operation was repeated 3 times. The resulting white powdery substance was sufficiently washed with dehydrated ether to obtain 1.32g (95%) of the title compound as a colorless solid.
Example 9 preparation of Boc-His (Boc) -Gly-Lys (z) -OBzl
Using the method of example 5, from 1.77g (5mmol) Boc-His (Boc) and 2.78g (6mmol) HCl Gly-Lys (z) -OBzl 2.56g (67%) of the title compound were obtained as a colorless solid. ESI-MS (M/e):765[ M + H] + 。
Example 10 preparation of HCl. His-Gly-Lys (z) -OBzl
From 2.29g (3mmol) Boc-His (Boc) -Gly-Lys (z) -OBzl 1.66g (92%) of the title compound was obtained as colorless solid using the method of example 8.
EXAMPLE 11 preparation of (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys (z) -OBzl (7)
Adding 1.32g (2mmol) of (3S) -1, 1-di (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-formyl-The (6) into 30mL of anhydrous tetrahydrofuran,0.49g (2.4mmol) DCC and 0.32g (2.4mmol) HOBt were stirred for 30 minutes in an ice bath. Then, 1.32g (2.2mmol) of HCl. His-Gly-Lys (z) -OBzl was added to the reaction mixture. N-methylmorpholine (NMM) was added dropwise to adjust the pH of the reaction mixture to 9. The reaction was carried out at room temperature for 8 hours. TLC showed compound 6 to disappear (dichloromethane/methanol, 15/1), Dicyclohexylurea (DCU) was filtered off and the filtrate was concentrated under reduced pressure. The residue was dissolved in 100mL of ethyl acetate and the solution was filtered to remove DCU. The filtrate was sequentially treated with 5% NaHCO 3 Aqueous solution (30 mL. times.3), saturated aqueous NaCl solution (30 mL. times.3), 5% KHSO 4 Aqueous wash (30 mL. times.3), saturated aqueous NaCl wash (30 mL. times.3), 5% NaHCO 3 The mixture was washed with an aqueous solution (30 mL. times.3) and with a saturated aqueous NaCl solution (30 mL. times.3), and dried over anhydrous sodium sulfate for 12 hours. Filtration and concentration of the filtrate under reduced pressure gave a yellow powder which was purified by silica gel column chromatography (dichloromethane/methanol, 15/1) to give 1.21g (50%) of the title compound as a yellow powder. ESI-MS (M/e) 1207[ M + H] + ； 1 H-NMR(300MHz,DMSO-d 6 ):δ/ppm＝11.82(s,1H),10.30(s,1H),8.63(s,1H),8,28(t,J＝6.0Hz 1H),8.09(m,1H),7.48(s,1H),7.38-7.31(m,12H),7.26(m,1H),7.01-6.95(m,2H),6.85(m,1H),5.12(s,1H),4.99(s,1H),4.47(m,1H),4.33(m,1H),3.93(m,1H),3.86-3.70(m,6H),3.05(m,2H),2.94(m,2H),2.11(m,2H),1.82(m,2H),1.74(m,4H),1.32(m,2H),1.17(m,3H),0.83(s,9H),0.76(s,9H),-0.009(m,6H),-0.03(s,3H),-0.11(s.3H)。
EXAMPLE 12 preparation of (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys (8)
To 10mL of methanol were added 0.60g (0.5mmol) of (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-lys (z) -OBzl and 0.04g Pd/C, stirred and passed through 12h of hydrogen, and TLC showed disappearance of compound 7 (ethyl acetate: water: glacial acetic acid ═ 4:1: 1). The palladium-carbon (Pd/C) was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was triturated with ether to give 0.43g (85%) of the title compound as a colourless solid. ESI-MS (M/e):1025[ M-H] - 。
EXAMPLE 13 preparation of (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys (9)
To 30mL of hydrogen chloride in ethyl acetate (4M)0.10g (0.1mmol) of (3S) -1, 1-bis (tert-butyldimethylsilyloxy) methyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys (8) was added, and The mixture was stirred for 4 hours in ice bath. TLC showed the disappearance of compound 8 (ethyl acetate: water: glacial acetic acid 4:1: 1). The reaction mixture was concentrated under reduced pressure, the residue was dissolved in anhydrous ethyl acetate, and the resulting solution was concentrated under reduced pressure. This operation was repeated 3 times. The colorless powder obtained is thoroughly washed with anhydrous diethyl ether and the residue is passed through 18 C column chromatography gave 0.045g (60%) of the title compound as a yellow solid, ESI-MS (M/e):755[ M + H] + ， 1 H-NMR(300MHz,DMSO-d 6 ):δ/ppm＝14.55(m,2H),11.16(s,1H),9.65(m,1H),9.20(m,1H),9.06(s,1H),8.92(d,J＝7.0Hz,1H),8.47(s,1H),8.45(s,1H),8.37(d,J＝7.0Hz,1H),8.02(s,2H),7.97(m,1H),7.48(m,1H),7.46(d,J＝8.0Hz,1H),7.37(d,J＝8.0Hz,1H),7.12(t,J＝7.2Hz,1H),7.02(t,J＝7.2Hz,1H),4.72(m,1H),4.64(m,1H),4.36(m,1H),4.22(m,1H),4.18-3.88(m,4H),3.79(m,1H),3.74(m,1H),3.62(s,1H),3.32(m,1H),3.04(m,3H),2.88(m,1H),2.75(m,2H),2.20(s,2H),1.90(m.2H),1.67(m,2H),1.57(m.2H),1.37(m,2H),1.01(t,J＝7.2Hz,3H)。
Example 14 evaluation of the Activity of Compound 9 to inhibit S180 transplantation mouse sarcoma
Experimental animals: ICR mice, male, 20 + -2 g, purchased from Experimental animals technology, Inc., Viton, Beijing. The tumor source is S180 sarcoma mouse, purchased from animal experiment center of department of medicine of Beijing university, and maintained by self-passage.
Administration dose and administration mode: the oral dose of the compound 9 of the present invention was 0.23. mu. mol/kg, the injection dose of the positive control doxorubicin was 2. mu. mol/kg, and the negative control was normal saline.
And (3) experimental operation: tumor fluid from a vigorously growing S180 sarcoma mouse was aseptically extracted, diluted (1: 2) with physiological saline and mixed well to give a tumor cell suspension, which was then stained with freshly prepared 0.2% trypan blue and mixed well. The blue stained cells were dead cells, while the non-stained cells were live cells. Then, the number was counted by a white blood cell counting method and the cell concentration and the cell viability were calculated as follows.
Cell concentration (cell number/mL) 4 Large Square Living cell number/4X 10 4 X dilution factor
The cell survival rate was live cell number/(live cell number + dead cell number) × 100%
Preparing tumor solution with survival rate of more than 90% into 1.5 × 10 by homogenizing method 7 Each cell suspension was subcutaneously inoculated to the axilla of ICR mice at a concentration of 0.1mL/10 g/mouse, to prepare S180 tumor-bearing mice. The administration was started 7 days after tumor inoculation, once a day, for a total of 10 times. After day 17, mice were sacrificed by cervical dislocation after ether anesthesia, then the right axillary tumor growth sites of the mice were fixed with forceps, the skin was cut open, the tumors were exposed, blunt dissection, and then weighed.
The experimental results are as follows: the results are shown in Table 1.
TABLE 1 Activity of Compound 9 to inhibit the growth of S180 transplanted mouse sarcoma
n-12, a) to saline ratio P <0.01, b) to doxorubicin ratio P >0.05.
The results show that the antitumor activity of compound 9 at the 0.23 μmol/kg oral dose is not only significantly stronger than that of normal saline but also has no significant difference from doxorubicin at the 2 μmol/kg injection dose. It can be seen that compound 9 of the present invention has outstanding technical effects.
Example 15 evaluation of Compound 9 Activity for inhibiting Lung metastasis in mouse Lewis Lung cancer mice
Experimental animals: c57BL/6 mice, male, 20. + -.2 g, purchased from Experimental animals technologies, Inc. of Wei Tony, Beijing.
Administration dose and administration mode: the oral dose of the compound 9 of the present invention was 0.23. mu. mol/kg, the injection dose of the positive control RGDS tetrapeptide was 20. mu. mol/kg, and the negative control was physiological saline.
The experimental method comprises the following steps: the experiment adopts a mouse Lewis anti-lung cancer metastasis model.
And (3) experimental operation: lewis mouse lung carcinoma cells (LLC) were purchased from ATCC. DMEM medium was used. The culture medium contains 10% inactivated fetal calf serum, 1 × 10 5 U/L cyanAnd streptomycin at 100 mg/L. Lewis mouse lung cancer cells were passaged once a day according to the adherent cell culture method. And (4) enriching cells. When the cells are in good growth and in the logarithmic growth phase, the cells are digested. Adjusting the cell concentration to 2X 10 with physiological saline 7 Counts per mL, trypan blue staining indicated viable cell number>95 percent. Inbred C57BL/6 male mice were taken, left-handed mice were fixed, the right anterior limb axillary skin of the mice was disinfected with 75% ethanol, and Lewis mouse lung cancer cell suspension (0.2 mL/mouse) was injected subcutaneously into the axillary region of the mice by holding a 1mL sterile syringe in the right hand. Tumors of about 4-5mm in diameter can develop 10 days after inoculation. Anesthetizing the Lewis lung cancer tumor-bearing mouse with ether, removing cervical vertebra, killing, soaking in 75% ethanol for 10min, stripping tumor body on a clean bench, shearing in a sterile plate, placing in a glass tissue homogenizer, lightly grinding with physiological saline pre-cooled to 4 deg.C according to the ratio of tumor mass (g) to physiological saline (mL) of 1:3 to obtain cell suspension, sieving with 200 mesh cell sieve to obtain single cell suspension, and adjusting cell concentration with physiological saline to 2 × 10 7 Counts per mL, trypan blue staining indicated viable cell number>95％。
Inbred C57BL/6 male mice were taken, left-handed mice were fixed, the right anterior limb axillary skin of the mice was disinfected with 75% ethanol, and Lewis mouse lung cancer cell suspension (0.2 mL/mouse) was injected subcutaneously into the axillary region of the mice by holding a 1mL sterile syringe in the right hand. Tumors that outgrow 10 days after inoculation with diameters of about 4-5mm were measured and were randomized to the mean tumor diameter. Dosing was then started 1 time a day for a total of 10 times. Tumor volumes were measured and recorded every two days. After day 22, mice were ether anesthetized, cervical vertebrae were removed and sacrificed, tumors were removed and weighed, and the number of nodules of lung metastases of the tumors was recorded.
The experimental results are as follows: the results are shown in Table 2.
TABLE 2 Activity of Compound 9 for inhibiting pulmonary metastasis in Lewis lung carcinoma mice
n-12, a) P <0.01 compared to saline group, b) to RGDS ratio P >0.05.
The results show that the activity of the compound 9 of the invention for inhibiting the lung metastasis of Lewis lung cancer mice under the oral dose of 0.23 mu mol/kg is not only obviously stronger than that of normal saline, but also has no significant difference with RGDS under the injection dose of 20 mu mol/kg. It can be seen that compound 9 of the present invention has outstanding technical effects.
EXAMPLE 16 evaluation of the Activity of Compound 9 to inhibit tumor cell migration
The experimental method comprises the following steps: collecting A549 cells with good growth state in logarithmic phase, digesting with 0.25% pancreatin, observing under the mirror, adding serum to stop digestion, centrifuging at 3000rpm for 3min, counting, and preparing into single cell suspension with density of 2 × 10 6 one/mL. 100. mu.L of cell suspension was added to each well of the upper chamber of the Transwell chamber, and a solution of Compound 9 was added to give a final concentration of 20. mu.M. The lower chamber was filled with 600. mu.L of 1640 medium containing 10% FBS at 37 ℃ and 5% CO 2 Culturing in an incubator for 6 hr, wiping off matrigel and cells in the upper chamber with cotton swab, fixing cells with 4% paraformaldehyde for 30min, removing the fixing solution by suction, and washing with PBS solution for 3 times; staining with 0.1% crystal violet staining solution for 15min, removing staining solution, washing with PBS solution for 3 times, selecting 9 fields in each chamber, taking pictures, and counting the number of cells by (
One) is shown.
The experimental results are as follows: the results are shown in Table 3.
TABLE 3 Activity of Compound 9 against migration of tumor cells
n-6, a) to blank control ratio P <0.05, to RGDS ratio P >0.05.
The result shows that the compound 9 can obviously inhibit the migration of the human non-small cell lung cancer cell A549. It can be seen that compound 9 of the present invention has outstanding technical effects.
EXAMPLE 17 evaluation of the Activity of Compound 9 to inhibit tumor cell invasion
The experimental method comprises the following steps: matrigel, which was stored in a refrigerator at-20 c as a yellow solid in advance, was put in a refrigerator at 4 c for about 12 hours to be a pink liquid with good fluidity. Adding 240 μ L Matrigel into 960 μ L serum-free culture medium required for corresponding tumor cells, diluting by 5 times, blowing to disperse uniformly, adding 100 μ L Matrigel per well, adding 5% CO at 37 deg.C 2 The cell incubator is incubated for 5 hours, so that the matrigel is uniformly paved in the small holes of the polycarbonate membrane. Carefully remove the supernatant with a pipette, add 50. mu.L of the corresponding serum-free medium, and re-incubate at 37 ℃ with 5% CO 2 Is incubated in the incubator for 30 min. After that, the residual liquid in the upper chamber was carefully aspirated by a pipette gun for use.
Collecting A549 cells with good growth state in logarithmic phase, digesting with 0.25% pancreatin, observing under the mirror, adding serum to stop digestion, centrifuging at 3000rpm for 3min, counting, and preparing into single cell suspension with density of 2 × 10 6 one/mL. 100. mu.L of cell suspension was added to each well of the upper chamber of the Transwell chamber, and a solution of Compound 9 was added to give a final concentration of 20. mu.M. The lower chamber was filled with 600. mu.L of 1640 medium containing 10% FBS, placed at 37 ℃ and 5% CO 2 Culturing for 12h in the cell incubator, wiping off matrigel and cells in the upper chamber by using a cotton swab, fixing the cells by using 4% paraformaldehyde for 30min, sucking out the fixing solution, washing for 3 times by using a PBS solution, dyeing for 15min by using 0.1% crystal violet dye solution, sucking out the dyeing solution, washing for 3 times by using the PBS solution, selecting 9 visual fields in each chamber for photographing and counting, wherein the number of the cells is calculated by (
One) is shown.
The experimental results are as follows: the results are shown in Table 4.
TABLE 4 Activity of Compound 9 against tumor cell invasion
Claims (4)
1. The structural formula of The (3S) -1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys,
2. a process for The preparation of (3S) -1, 1-dimethylol-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys according to claim 1, comprising 10 steps:
(1) preparing (3S) -1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-carboxylic acid;
(2) preparing (3S) -1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-carboxylic acid methyl ester;
(3) preparing (3S) -1, 1-di (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-carboxylic acid methyl ester;
(4) preparing (3S) -1, 1-di (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-carboxylic acid;
(5) adopting Dicyclohexylcarbodiimide (DCC) as a condensing agent and 1-hydroxybenzotriazole (HOBt) as a catalyst to prepare (3S) -1, 1-di (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-formyl-The-OMe through liquid phase condensation;
(6) preparing (3S) -1, 1-di (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-formyl-The;
(7) DCC is used as a condensing agent, HOBt is used as a catalyst, and liquid phase condensation is carried out to prepare HCl, His-Gly-Lys (z) -OBzl;
(8) DCC is used as a condensing agent, HOBt is used as a catalyst to prepare (3S) -1, 1-di (tert-butyl dimethyl siloxy) methyl-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys (z) -OBzl through liquid phase condensation;
(9) preparing (3S) -1, 1-di (tert-butyldimethylsilyloxy) methyl-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys;
(10) preparing (3S) -1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys.
3. Use of (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys according to claim 1 for The preparation of an anti-tumor medicament.
4. The use of (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys of claim 1 in The preparation of a medicament for The treatment of tumor metastasis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910273811.1A CN111793113B (en) | 2019-04-07 | 2019-04-07 | Synthesis, activity and application of dihydroxymethyl tetrahydrocarboline-3-formyl-The-HGK |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910273811.1A CN111793113B (en) | 2019-04-07 | 2019-04-07 | Synthesis, activity and application of dihydroxymethyl tetrahydrocarboline-3-formyl-The-HGK |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111793113A CN111793113A (en) | 2020-10-20 |
| CN111793113B true CN111793113B (en) | 2022-08-05 |
Family
ID=72804979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910273811.1A Expired - Fee Related CN111793113B (en) | 2019-04-07 | 2019-04-07 | Synthesis, activity and application of dihydroxymethyl tetrahydrocarboline-3-formyl-The-HGK |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111793113B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013147649A2 (en) * | 2012-03-29 | 2013-10-03 | ХОЛИН, Максим Николаевич | Inhibitors of the pi3k/akt/ikk/nf-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases |
| CN108976283A (en) * | 2017-05-30 | 2018-12-11 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GLDV, synthesis, activity and application |
| CN109111502A (en) * | 2017-06-23 | 2019-01-01 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GGPRP, synthesis, activity and application |
| CN109134605A (en) * | 2017-06-16 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GYIGSK, synthesis, activity and application |
| CN109134607A (en) * | 2017-06-16 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GRGDS, synthesis, activity and application |
| CN109134604A (en) * | 2017-06-16 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GRGDF, synthesis, activity and application |
| CN109134606A (en) * | 2017-06-16 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GRGDV, synthesis, activity and application |
| CN109134603A (en) * | 2017-06-13 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GYIGSR, synthesis, activity and application |
-
2019
- 2019-04-07 CN CN201910273811.1A patent/CN111793113B/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013147649A2 (en) * | 2012-03-29 | 2013-10-03 | ХОЛИН, Максим Николаевич | Inhibitors of the pi3k/akt/ikk/nf-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases |
| CN108976283A (en) * | 2017-05-30 | 2018-12-11 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GLDV, synthesis, activity and application |
| CN109134603A (en) * | 2017-06-13 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GYIGSR, synthesis, activity and application |
| CN109134605A (en) * | 2017-06-16 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GYIGSK, synthesis, activity and application |
| CN109134607A (en) * | 2017-06-16 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GRGDS, synthesis, activity and application |
| CN109134604A (en) * | 2017-06-16 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GRGDF, synthesis, activity and application |
| CN109134606A (en) * | 2017-06-16 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GRGDV, synthesis, activity and application |
| CN109111502A (en) * | 2017-06-23 | 2019-01-01 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GGPRP, synthesis, activity and application |
Non-Patent Citations (2)
| Title |
|---|
| 四氢咔啉类纺锤体驱动蛋白抑制剂的合成和抗肿瘤活性研究;阮秀琴等;《药学学报》;20130712;第48卷(第7期);摘要 * |
| 天然β-咔啉衍生物合成及其活性研究;林志刚;《中国博士学位论文全文数据库 医药卫生科技辑》;20040215;E079-2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111793113A (en) | 2020-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109111501B (en) | Fatty amino acid modified indole ethanol derivative, and synthesis, activity and application thereof | |
| CN109081801B (en) | Acidic amino acid modified indoloethanol derivative, and synthesis, activity and application thereof | |
| CN105884862B (en) | B-carboline acyl-tryptophan of RGD tetrapeptide modification, preparation, nanostructure, activity and application | |
| CN111793113B (en) | Synthesis, activity and application of dihydroxymethyl tetrahydrocarboline-3-formyl-The-HGK | |
| CN108976159B (en) | Aromatic amino acid modified indole ethanol derivative, and synthesis, activity and application thereof | |
| CN111793114B (en) | Synthesis, activity and application of dihydroxymethyl tetrahydro-carboline-3-formyl-The-HGE | |
| CN111793115A (en) | Dimethylol tetrahydro carboline-3-formyl-The-EDG, synthesis, activity and application thereof | |
| CN112898376B (en) | Dioxane-modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, antitumor activity thereof and application thereof | |
| CN112094321B (en) | His-Gly-Glu modified methotrexate, synthesis, anti-transfer activity and application thereof | |
| CN107686508B (en) | Adriamycin-RGDS, its synthesis, activity and application | |
| CN112898379B (en) | Dioxane-modified tetrahydrocarboline-3-formyl-The-HGE, preparation thereof, antitumor activity thereof and application thereof | |
| CN112979750B (en) | Dioxohexa-ring modified tetrahydrocarboline-3-formyl-The-EDG, preparation thereof, anti-transfer activity thereof and application thereof | |
| CN112094317B (en) | His-Gly-Lys modified methotrexate, synthesis, anti-transfer activity and application thereof | |
| CN112300246B (en) | 5-fluorouracil modified by aspartyl theanine RGDS, and synthesis, activity and application thereof | |
| CN112300244B (en) | 5-fluorouracil modified by theanine alone or together with RGDS, and synthesis, activity and application thereof | |
| CN112390854B (en) | 5-fluorouracil modified by theanine and RGDS together, and synthesis, activity and application thereof | |
| CN109134595B (en) | Theanyl amino acid benzyl ester modified curcumin, and synthesis, activity and application thereof | |
| CN112300245B (en) | RGDS and theanine co-modified 5-fluorouracil, and synthesis, activity and application thereof | |
| CN112010811B (en) | 5-fluorouracil modified by theanine and phenylalanine together, and synthesis, activity and application thereof | |
| CN112110987B (en) | 5-fluorouracil modified by asparaginyl theanine and phenylalanine, synthesis, activity and application thereof | |
| CN110551120B (en) | 6-amino amido n-hexanoyl carboline benzyl carboxylate, preparation, activity and application thereof | |
| CN112094319B (en) | Glu-Asp-Gly modified methotrexate, synthesis, anti-transfer activity and application thereof | |
| CN112979752B (en) | Dioxane-modified tetrahydrocarboline-3-formyl-The-EDG, preparation thereof, antitumor activity thereof and application thereof | |
| CN102532262A (en) | Preparation of fatty acid-RGD-fatty alcohol conjugate mediated epirubicin targeted liposome and evaluation on anticancer activity | |
| CN116410216B (en) | Small molecular boron medicine, preparation method thereof, pharmaceutical composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220805 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |